Investors Sweet On KaNDy Menopause Treatment
Executive Summary
Armed with a fresh injection of £25m, the UK's KaNDy is about to begin Phase IIb trials of a dual mechanism therapy it believes will be a transformational treatment to tackle two key symptoms of the menopause, hot flashes and night time awakenings.
You may also be interested in...
Menopausal Symptoms Cooled By KaNDy's Dual Neurokinin Antagonist
Faster relief of debilitating menopausal symptoms in early-stage clinical trial results suggest a potential new class of products being evaluated by UK biotech KaNDy Therapeutics may be useful against the condition.
GSK Spin-Off Launches KaNDy To Tackle Key Symptoms Of Menopause
NeRRe Therapeutics has set up a new entity around a drug which it believes could be an effective alternative to hormone replacement therapy for hot flashes that may rapidly reduce debilitating sleep disturbance.
Astellas Flashes Cash For Ogeda's Women's Health Drug
Astellas is spending €500m up front to acquire Belgium-based biotech Ogeda for its pipeline of women's health products, including Phase II drug candidate fezolinetant, a non-hormonal treatment for menopausal hot flashes that could be on the market within five years.